Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats

View through CrossRef
ObjectiveThis study aims to evaluate the effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats and to explore the mechanism of Kuntai capsule on the ovarian function of rats.MethodsSeventy-four female Sprague-Dawley rats were used for this study. Eight of the rats were randomly assigned to the Control group. The remaining sixty-six rats were utilized to establish the POI model via Cisplatin and then randomly divided into four groups: the model Control group, the Estradiol group, and groups treated with low and high doses of Kuntai capsule. For the 28-day administration, the Control and model Control groups were intragastrically administered with 2.0 mL of 0.9% sodium chloride daily, the Estradiol group with 2.0 mL of Estradiol suspension (0.2mg/kg/d), and the low dose Kuntai capsule group and the high dose Kuntai capsule group with 2.0 mL of Kuntai capsule suspension (0.6g/kg/d, 1.8g/kg/d, respectively). Sex hormone levels, estrous cycle, and ovarian coefficient of the five groups were compared, histological sections analyzed follicle counts, and the protein expressions of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 in the ovarian tissue were detected by Western blotting.ResultsAfter the 28-day administration, the serum Estradiol and Follicle-Stimulating Hormone levels of the group treated with low dose of Kuntai capsule were not significantly different from the Control group, the serum anti-Müllerian Hormone level of the group treated with high dose of Kuntai capsule was significantly higher than the Estradiol group. The estrous cycle of the group treated with low dose of Kuntai capsule was significantly lower than the model Control group. Regarding ovarian coefficient, resting and growing follicles, growth differentiation factor 9, light chain 3 A-II, and Beclin 1 expression, both Kuntai capsule groups outperformed the model Control group with the statistical difference (P<0.05).ConclusionKuntai capsule can improve the estrous cycle and ovarian coefficient of rats with premature ovarian insufficiency, maintain the number of resting and growing follicles, and up-regulate the protein expression of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 of rats’ ovaries.
Title: The effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats
Description:
ObjectiveThis study aims to evaluate the effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats and to explore the mechanism of Kuntai capsule on the ovarian function of rats.
MethodsSeventy-four female Sprague-Dawley rats were used for this study.
Eight of the rats were randomly assigned to the Control group.
The remaining sixty-six rats were utilized to establish the POI model via Cisplatin and then randomly divided into four groups: the model Control group, the Estradiol group, and groups treated with low and high doses of Kuntai capsule.
For the 28-day administration, the Control and model Control groups were intragastrically administered with 2.
0 mL of 0.
9% sodium chloride daily, the Estradiol group with 2.
0 mL of Estradiol suspension (0.
2mg/kg/d), and the low dose Kuntai capsule group and the high dose Kuntai capsule group with 2.
0 mL of Kuntai capsule suspension (0.
6g/kg/d, 1.
8g/kg/d, respectively).
Sex hormone levels, estrous cycle, and ovarian coefficient of the five groups were compared, histological sections analyzed follicle counts, and the protein expressions of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 in the ovarian tissue were detected by Western blotting.
ResultsAfter the 28-day administration, the serum Estradiol and Follicle-Stimulating Hormone levels of the group treated with low dose of Kuntai capsule were not significantly different from the Control group, the serum anti-Müllerian Hormone level of the group treated with high dose of Kuntai capsule was significantly higher than the Estradiol group.
The estrous cycle of the group treated with low dose of Kuntai capsule was significantly lower than the model Control group.
Regarding ovarian coefficient, resting and growing follicles, growth differentiation factor 9, light chain 3 A-II, and Beclin 1 expression, both Kuntai capsule groups outperformed the model Control group with the statistical difference (P<0.
05).
ConclusionKuntai capsule can improve the estrous cycle and ovarian coefficient of rats with premature ovarian insufficiency, maintain the number of resting and growing follicles, and up-regulate the protein expression of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 of rats’ ovaries.

Related Results

Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
Impact of Kuntai Capsules on LIF, IGF-1 and EGF Expression in the Implantation Window of Endometrium in Mice
Impact of Kuntai Capsules on LIF, IGF-1 and EGF Expression in the Implantation Window of Endometrium in Mice
Objective: This study aims to investigate the influence of Kuntai capsules on the expression level of leukemia inhibitory factor (LIF), insulin-like growth factor-I (IGF-1) and epi...
Effectiveness of Cotreatment with Kuntai Capsule and Climen for Premature Ovarian Failure: A Meta‐Analysis
Effectiveness of Cotreatment with Kuntai Capsule and Climen for Premature Ovarian Failure: A Meta‐Analysis
Objective. To compare the treatment efficacy of Kuntai capsule with Climen only in the therapy of premature ovarian failure. Methods. Randomized controlled trials were electronical...
The efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis
The efficacy and safety of Kuntai capsule combined with leuprorelin acetate in the treatment of endometriosis
Abstract Background: Endometriosis (EMS) is one of the common diseases in women, which seriously affects the quality of life of women. Leuproreli...
Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism
Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism
This study evaluates the clinical effectiveness of combining kuntai capsule with hormone replacement therapy (HRT) in treating premature ovarian failure (POF) and its impact on ova...

Back to Top